Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Revenue	1.83B	1.62B	1.23B
Tyvaso Revenue Growth	12.92%	31.34%	41.32%
Remodulin Revenue	533.30M	538.10M	494.80M
Remodulin Revenue Growth	-0.89%	8.75%	-1.08%
Orenitram Revenue	483.50M	434.30M	359.40M
Orenitram Revenue Growth	11.33%	20.84%	10.55%
Unituxin Revenue	232.00M	238.70M	198.90M
Unituxin Revenue Growth	-2.81%	20.01%	8.75%
Adcirca Revenue	26.90M	23.80M	28.90M
Adcirca Revenue Growth	13.03%	-17.65%	-30.02%
Total Product Sales Revenue	3.11B	2.86B	2.32B
Total Product Sales Revenue Growth	8.76%	23.30%	20.45%
Revenue (Other)	22.90M	22.10M	11.80M
Revenue (Total)	3.13B	2.88B	2.33B
Revenue (Total) Growth	8.72%	23.63%	20.20%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	2.99B	2.74B	2.20B
United States Revenue Growth	9.13%	24.41%	21.39%
Rest-of-World Revenue	138.50M	137.70M	125.30M
Rest-of-World Revenue Growth	0.58%	9.90%	2.54%
Revenue (Total)	3.13B	2.88B	2.33B
Revenue (Total) Growth	8.72%	23.63%	20.20%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Gross Profit	1.61B	1.44B	1.09B
Tyvaso Gross Profit Growth	12.06%	32.44%	32.48%
Remodulin Gross Profit	478.70M	490.70M	456.60M
Remodulin Gross Profit Growth	-2.44%	7.47%	-2.06%
Orenitram Gross Profit	456.00M	405.90M	335.20M
Orenitram Gross Profit Growth	12.34%	21.09%	10.74%
Unituxin Gross Profit	218.20M	224.30M	182.40M
Unituxin Gross Profit Growth	-2.72%	22.97%	7.42%
Adcirca Gross Profit	15.40M	13.70M	16.60M
Adcirca Gross Profit Growth	12.41%	-17.47%	-29.36%
Total Product Sales Gross Profit	2.78B	2.57B	2.08B
Total Product Sales Gross Profit Growth	8.12%	23.89%	16.55%
Gross Profit (Other)	-9.90M	-4.80M	-6.50M
Gross Profit (Total)	2.77B	2.57B	2.07B
Gross Profit (Total) Growth	7.94%	24.04%	15.99%

Updated Oct 29, 2025. Data Source: Fiscal.ai.